RxDoctor Payments DataLook up a doctor →

Timothy Goodson, MD

Urology · Little Rock, ARNPI 1578538252

Payments from drug & device makers

$147,278in general payments, 2019–2025

Across 604 payments — averaging $243.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cryo Specialty Medical, LLC$125K
  • Astellas Pharma US Inc$3K
  • AbbVie$3K
  • Pfizer$3K
  • Coloplast$3K
  • Astellas Pharma Global Development$2K
  • plus $9K from 30 others

What the payments were for

  • Consulting fees$3,9203%
  • Speaking & faculty fees$18,32512%
  • Travel & lodging$8261%
  • Food & beverage$13,0719%
  • Education$1360%
  • Ownership interest$111,00075%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,278 in reported general payments places this provider in the 95th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,796,037
Medicare patients
1,759
Services billed
24,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide38$540,495
XtandiEnzalutamide38$533,358
NubeqaDarolutamide31$406,343
MyrbetriqMirabegron231$139,533
GemtesaVibegron170$107,050
OrgovyxRelugolix23$59,219
ElmironPentosan Polysulfate Sodium39$29,965
Tamsulosin Hcl1,146$13,955
Oxybutynin Chloride ErOxybutynin Chloride539$8,934
Finasteride725$7,617
Trimethoprim123$6,303
Estradiol38$2,427
Dutasteride49$1,523
Potassium Citrate ErPotassium Citrate44$1,318
Ciprofloxacin Hcl268$1,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$3,395$672,891269 claims
Johnson & JohnsonErleada$794$540,49538 claims
BayerNubeqa$241$406,34331 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$940$166,269193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 urology providers in Arkansas.

Other urology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →